CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

News Creative Medical Technology Holdings, Inc.

Equities

CELZ

US22529Y4089

Delayed Nasdaq Other stock markets 16:30:00 2024-05-08 EDT			5-day change	1st Jan Change
4.43 ^USD	-3.70%		-3.17%	-3.90%

03-22	Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	CI
03-22	Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Creative Medical Technology Holdings Provides Corporate Update	03-27	BU
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	03-22	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Creative Medical Shares Rise 37% After FDA Authorization for CELZ-201	03-07	DJ
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access	03-07	BU
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access	03-07	CI
Creative Medical Technology Holdings Gets US FDA Orphan Drug Designation; Shares Rise	03-06	MT
Private Payrolls Data, Upcoming Powell Testimony Drive Higher Premarket Action for US Equity Futures	03-06	MT
Creative Medical Shares Rally Premarket on FDA Orphan Designation	03-06	DJ
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Ahead of Powell Testimony	03-06	MT
Top Premarket Gainers	03-06	MT
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy	03-06	BU
Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem	12-20	CI
Creative Medical Technology Holdings Provides Corporate Update	11-15	PR
Tranche Update on Creative Medical Technology Holdings, Inc.'s Equity Buyback Plan announced on June 12, 2023.	11-14	CI
Creative Medical Technology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem Novel Cell Therapy to Treat Chronic Lower Back Pain	23-10-11	AQ
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain	23-10-10	PR
Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain	23-10-10	CI
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine using AlloStem for the Treatment of Chronic Lower Back Pain	23-09-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Creative Medical Technology Holdings, Inc.

Equities

CELZ

US22529Y4089

Summary

Filters